Payment overview · 2025
General Payments
$1,692.14
40 reported records · 14 companies
Healthcare provider profile · identity verified
Harold Mark Cotler, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WALL TOWNSHIP, NJ · NPI 1659355832
Verified facts
What the public records show
CMS Open Payments records show Harold Mark Cotler, D.O. received $1,692.14 in general payments during 2025 across 40 reported records.
W. L. Gore & Associates, Inc. accounted for 69.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Synthroid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $1,176.96 | 69.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.44 | 6.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.57 | 4.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.33 | 3.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.52 | 3.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.39 | 3.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.56 | 2.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.28 | 1.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.50 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.62 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.52 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.20 | 1.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.28 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,692.14 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE SYNECOR Biomaterial Normalized: gore synecor biomaterial |
Device | W. L. Gore & Associates, Inc. | $506.00 | 5 | 2025 |
Source payment records
|
|||||
| GORE ENFORM Preperitoneal Biomaterial Normalized: gore enform preperitoneal biomaterial |
Device | W. L. Gore & Associates, Inc. | $347.73 | 3 | 2025 |
Source payment records
|
|||||
| GORE ENFORM Intraperitoneal Biomaterial Normalized: gore enform intraperitoneal biomaterial |
Device | W. L. Gore & Associates, Inc. | $323.23 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $78.57 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $54.97 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.64 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $50.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 56 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
198 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 930 | 265 |
| Atorvastatin Calcium | Atorvastatin Calcium | 702 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 562 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 114 |
| Losartan Potassium | Losartan Potassium | 415 | 112 |
| Lisinopril | Lisinopril | 397 | 109 |
| Alprazolam | Alprazolam | 352 | 82 |
| Metformin Hcl | Metformin Hcl | 330 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 83 |
| Montelukast Sodium | Montelukast Sodium | 306 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 65 |
| Eliquis | Apixaban | 198 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 54 |
| Gabapentin | Gabapentin | 185 | 45 |
| Ezetimibe | Ezetimibe | 180 | 49 |
| Allopurinol | Allopurinol | 173 | 40 |
| Furosemide | Furosemide | 163 | 47 |
| Carvedilol | Carvedilol | 161 | 37 |
| Simvastatin | Simvastatin | 155 | 43 |
| Omeprazole | Omeprazole | 152 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 28 |
| Prednisone | Prednisone | 146 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 33 |
| Tramadol Hcl | Tramadol Hcl | 112 | 37 |
| Trazodone Hcl | Trazodone Hcl | 104 | 25 |
| Sertraline Hcl | Sertraline Hcl | 103 | 25 |
| Farxiga | Dapagliflozin Propanediol | 100 | 20 |
| Potassium Chloride | Potassium Chloride | 98 | 27 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 94 | 16 |
| Mirtazapine | Mirtazapine | 88 | 18 |
| Famotidine | Famotidine | 86 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 76 | 19 |
| Methocarbamol | Methocarbamol | 72 | 29 |
| Repaglinide | Repaglinide | 69 | 24 |
| Azithromycin | Azithromycin | 68 | 59 |
| Valsartan | Valsartan | 67 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 14 |
| Xarelto | Rivaroxaban | 65 | 18 |
| Clonazepam | Clonazepam | 63 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 63 | 21 |
| Finasteride | Finasteride | 62 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 15 |
| Synthroid | Levothyroxine Sodium | 56 | 16 |
| Jardiance | Empagliflozin | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | 13 |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Ozempic | Semaglutide | 47 | 14 |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 13 |
| Ketoconazole | Ketoconazole | 44 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 20 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Meloxicam | Meloxicam | 40 | 11 |
| Ramipril | Ramipril | 40 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Spironolactone | Spironolactone | 35 | 14 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 12 |
| Cefprozil | Cefprozil | 32 | 29 |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Oxycontin | Oxycodone Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Ciclopirox | Ciclopirox | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 25 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Triazolam | Triazolam | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Wellbutrin Sr | Bupropion Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Zaleplon | Zaleplon | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Crestor | Rosuvastatin Calcium | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 12 |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Febuxostat | Febuxostat | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Singulair | Montelukast Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,692.14 · 40 records | W. L. Gore & Associates, Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, GORE ENFORM Intraperitoneal Biomaterial, GORE ENFORM Preperitoneal Biomaterial, GORE SYNECOR Biomaterial, GVOKE HYPOPEN, KISUNLA, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, SYNTHROID, UBRELVY, VRAYLAR, Vest Therapy Und, ZAVZPRET, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error